Cellusion

Cellusion is dedicated to realize a new treatment method that manufactures corneal endothelium replacement cells from induced pluripotent (iPS) cells using a unique approach and transplants these cells into the eye using a syringe, enabling the cells to settle into the cornea within three hours post-surgery. Experimental studies on monkeys and other animals have confirmed the survival of the transplanted cells. Cellusion is now preparing for clinical research to ultimately address the needs of approximately 13 million patients worldwide awaiting corneal transplants, aiming to enhance the quality of life for those in need.